I'm wondering at what point the European University and pharmaceutical company that is using Kevetrin will reveal their identities?  My guess is that if the combo works, the pharma company gets first shot at partnering with CTXI.  The only thing is that all of the pharma companies are going to be on the lookout for this study and some one will squeal.  They might as well just let the cat out of the bag lol.